NCT00753545 2025-02-03Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian CancerAstraZenecaPhase 2 Completed265 enrolled 25 charts 1 FDA
NCT02987543 2023-10-06Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)AstraZenecaPhase 3 Completed387 enrolled 16 charts 2 FDA